Chugai Pharmaceutical (OTCMKTS:CHGCY) Hits New 1-Year Low – Should You Sell?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY)’s share price hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $20.00 and last traded at $20.8110, with a volume of 53021 shares. The stock had previously closed at $20.78.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Nomura upgraded shares of Chugai Pharmaceutical to a “hold” rating in a research report on Tuesday, September 1st. The Goldman Sachs Group raised Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Monday, June 15th. Zacks Research raised Chugai Pharmaceutical to a “hold” rating in a report on Friday, May 29th. Finally, UBS Group downgraded Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy”.

Chugai Pharmaceutical Stock Performance

The stock’s fifty day moving average price is $21.78 and its 200-day moving average price is $24.58. The firm has a market cap of $68.33 billion, a PE ratio of 22.57 and a beta of 0.59.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its earnings results on Friday, July 24th. The company reported $0.22 earnings per share for the quarter. The company had revenue of $2.14 billion for the quarter, compared to analyst estimates of $2.38 billion. Chugai Pharmaceutical had a net margin of 35.09% and a return on equity of 23.76%. Sell-side analysts forecast that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.96 earnings per share for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Tokyo. Founded in 1925, the company focuses on discovering, developing, manufacturing and commercializing prescription medicines, with an emphasis on biotechnology and innovative therapies for serious and unmet medical needs.

Chugai’s principal therapeutic areas include oncology, hematology, immunology, neuroscience and renal diseases. Its products include Actemra (known as RoActemra in some markets) for inflammatory and immune-related conditions, Hemlibra for hemophilia A, and Alecensa for certain forms of lung cancer.